These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 15037557)

  • 21. Prognostic significance of serial changes in left ventricular mass in essential hypertension.
    Verdecchia P; Schillaci G; Borgioni C; Ciucci A; Gattobigio R; Zampi I; Reboldi G; Porcellati C
    Circulation; 1998 Jan 6-13; 97(1):48-54. PubMed ID: 9443431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Is antihypertensive treatment a risk factor of coronary disease? Therapy-related triglyceride increase nor diabetes increase the risk].
    Samuelsson O; Pennert K; Andersson O; Berglund G; Hedner T; Persson B; Wedel H; Wilhelmsen L
    Lakartidningen; 1998 Mar; 95(11):1120-3. PubMed ID: 9542820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients.
    Muiesan ML; Salvetti M; Monteduro C; Bonzi B; Paini A; Viola S; Poisa P; Rizzoni D; Castellano M; Agabiti-Rosei E
    Hypertension; 2004 Apr; 43(4):731-8. PubMed ID: 15007041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isolated ambulatory hypertension and changes in target organ damage in treated hypertensive patients.
    Cuspidi C; Meani S; Fusi V; Valerio C; Catini E; Magrini F; Zanchetti A
    J Hum Hypertens; 2005 Jun; 19(6):471-7. PubMed ID: 15744331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sleep-time blood pressure: prognostic value and relevance as a therapeutic target for cardiovascular risk reduction.
    Hermida RC; Ayala DE; Fernández JR; Mojón A
    Chronobiol Int; 2013 Mar; 30(1-2):68-86. PubMed ID: 23181592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Wedel H; Lindholm LH; Dahlöf B;
    JAMA; 2004 Nov; 292(19):2343-9. PubMed ID: 15547161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Night-day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension.
    Fagard RH; Thijs L; Staessen JA; Clement DL; De Buyzere ML; De Bacquer DA
    J Hum Hypertens; 2009 Oct; 23(10):645-53. PubMed ID: 19225527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk.
    Bakris GL; Sowers JR
    Hypertension; 2004 May; 43(5):941-2. PubMed ID: 15037556
    [No Abstract]   [Full Text] [Related]  

  • 29. Inappropriate left ventricular mass changes during treatment adversely affects cardiovascular prognosis in hypertensive patients.
    Muiesan ML; Salvetti M; Paini A; Monteduro C; Galbassini G; Bonzi B; Poisa P; Belotti E; Agabiti Rosei C; Rizzoni D; Castellano M; Agabiti Rosei E
    Hypertension; 2007 May; 49(5):1077-83. PubMed ID: 17372030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
    Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diabetes and cardiovascular events in hypertensive patients.
    Alderman MH; Cohen H; Madhavan S
    Hypertension; 1999 May; 33(5):1130-4. PubMed ID: 10334799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Management of hypertensive patients with left ventricular hypertrophy].
    Ambrosioni E
    Presse Med; 2002 Oct; 31 Spec No 2():S13-6. PubMed ID: 12355999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
    Oikarinen L; Nieminen MS; Viitasalo M; Toivonen L; Jern S; Dahlöf B; Devereux RB; Okin PM;
    Hypertension; 2004 May; 43(5):1029-34. PubMed ID: 15037560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic Syndrome and Cardiovascular Risk in Elderly Treated Hypertensive Patients.
    Pierdomenico SD; Pierdomenico AM; Di Tommaso R; Coccina F; Di Carlo S; Cuccurullo F; Porreca E
    Am J Hypertens; 2016 Mar; 29(3):365-71. PubMed ID: 26224400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients.
    Okin PM; Devereux RB; Nieminen MS; Jern S; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Julius S; Snapinn S; Dahlöf B;
    Hypertension; 2004 Jul; 44(1):48-54. PubMed ID: 15173125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Excess mortality associated with diuretic therapy in diabetes mellitus.
    Warram JH; Laffel LM; Valsania P; Christlieb AR; Krolewski AS
    Arch Intern Med; 1991 Jul; 151(7):1350-6. PubMed ID: 1823530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic influence of office and ambulatory blood pressures in resistant hypertension.
    Salles GF; Cardoso CR; Muxfeldt ES
    Arch Intern Med; 2008 Nov; 168(21):2340-6. PubMed ID: 19029499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The choice of antihypertensive therapy in patients with the metabolic syndrome--time to change recommendations?
    Hilgers KF; Mann JF
    Nephrol Dial Transplant; 2008 Nov; 23(11):3389-91. PubMed ID: 18687734
    [No Abstract]   [Full Text] [Related]  

  • 39. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.
    Ma L; Wang W; Zhao Y; Zhang Y; Deng Q; Liu M; Sun H; Wang J; Liu L
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):137-42. PubMed ID: 22329591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular risk of essential hypertension: influence of class, number, and treatment-time regimen of hypertension medications.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):315-27. PubMed ID: 23181712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.